Tips from Other Journals

Does Aspirin Plus Clopidogrel Prevent Cardiovascular Events?



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2006 Oct 1;74(7):1204-1206.

Aspirin prevents cardiovascular events in patients at increased risk of cardiac disease, and aspirin therapy plus clopidogrel (Plavix) adds protection in patients with myocardial infarction and unstable angina and after coronary stenting compared with aspirin alone. However, it is unknown if adding clopidogrel to aspirin prevents atherothrombotic events in high-risk patients. To address this issue, Bhatt and colleagues compared dual anti-platelet treatment with aspirin alone.

CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance), a prospective, randomized, double-blind, placebo-controlled trial, included more than 15,000 patients with clinical cardiovascular disease or multiple cardiac risk factors. Participants received aspirin plus placebo or aspirin plus clopidogrel. Patients were 45 years or older and had one of the following: multiple cardiac risk factors (i.e., two major or three minor or one major and two minor cardiovascular risk factors [see accompanying table on page 1206]), coronary heart disease, cerebrovascular disease, or symptomatic peripheral arterial disease. Patients who met criteria for clopidogrel treatment (e.g., those with a recent myocardial infarction or acute coronary syndrome) were excluded. Patients were receiving previously established treatments (e.g., statins) at the discretion of their physicians.

Patients were followed for a mean of 28 months. The primary end point was a combination of myocardial infarction, stroke, or cardiovascular death, and the primary safety measure was bleeding events. Secondary end points included the primary end point plus hospitalization for unstable angina, revascularization, or transient ischemic attack; individual primary and secondary end points; and all-cause mortality. The average age of participants was 64 years, and most patients were white (80 percent) and men (70 percent). Approximately 75 percent had established cardiovascular disease (i.e., symptomatic), and the remaining participants were included because of risk (i.e., asymptomatic).

There was no significant difference in the primary end point, which occurred in 6.8 percent of the combination group and in 7.3 percent of the aspirin-only group (P = .22). The combined secondary outcome occurred in 16.7 percent of the combination group and in 17.9 percent of the aspirin-only group (P = .04). There was no significant difference in severe bleeding events between the two groups, although moderate bleeding occurred in 2.1 percent of the combination group and in 1.3 percent of the aspirin-only group (P < .001). Subgroup analysis revealed that primary events occurred in 6.6 percent of asymptomatic patients in the combination group and in 5.5 percent of asymptomatic patients in the aspirin-only group (P = .20). This did not occur in symptomatic patients, with 6.9 percent of patients in the combination group and 7.9 percent in the aspirin-only group (P = .046) experiencing primary events. Furthermore, asymptomatic patients in the combination group had an increased risk of all-cause mortality (5.4 versus 3.8 percent, P = .04) and cardiovascular death (3.9 versus 2.2 percent, P = .01)

The authors conclude that clopidogrel added no significant benefit in preventing atherothrombotic events in patients with stable cardiovascular disease or multiple risk factors. The authors estimate a trade-off of 94 prevented ischemic events at a cost of 93 moderate to severe bleeding events. They also conclude that the subgroup observations deserve further study before changes are made to clinical practice. Because of the increased risk of cardiovascular and all-cause mortality in asymptomatic patients, physicians should caution against expanding the use of combined antiplatelet therapy beyond already established indications.

Risk Factors for Atherothrombosis in the CHARISMA Trial

Major risk factors

Type 1 or 2 diabetes

Diabetic nephropathy

Ankle-brachial index score less than 0.9

Asymptomatic carotid stenosis of 70 percent or more

One or more carotid plaque

Minor risk factors

Systolic blood pressure 150 mm Hg or higher, despite three months of treatment

Primary hypercholesterolemia

Active smoker (more than 15 cigarettes per day)

Men 65 years or older

Women 70 years or older


CHARISMA = Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance.

Risk Factors for Atherothrombosis in the CHARISMA Trial

View Table

Risk Factors for Atherothrombosis in the CHARISMA Trial

Major risk factors

Type 1 or 2 diabetes

Diabetic nephropathy

Ankle-brachial index score less than 0.9

Asymptomatic carotid stenosis of 70 percent or more

One or more carotid plaque

Minor risk factors

Systolic blood pressure 150 mm Hg or higher, despite three months of treatment

Primary hypercholesterolemia

Active smoker (more than 15 cigarettes per day)

Men 65 years or older

Women 70 years or older


CHARISMA = Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance.

Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. April 20, 2006;354:1706–17.

editor’s note: Although clopidogrel has been proven to add benefit in patients with acute events (e.g., myocardial infarction), this benefit did not carry over to patients with stable disease or elevated risk. A related editorial discusses the issue of subgroup findings in the CHARISMA trial.1 The authors cautioned that, although subgroup analysis suggested benefit or harm, drawing firm conclusions is hazardous. For example, one could suggest a benefit (although small) for the symptomatic subgroup. However, given the major coronary events and significant cardiovascular risk factors that were present in both subgroups, the symptomatic subgroup may not truly be different. Unless future studies indicate otherwise, dual antiplatelet therapy should be avoided for asymptomatic and symptomatic subgroups identified in the CHARISMA trial.—C.C.

REFERENCE

1. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA [Editorial]. N Engl J Med. 2006;354:1744–6.

 


Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article